MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- CIPLA - GLENMARK PHARMA
CIPLA vs GLENMARK PHARMA - Comparison Results
CIPLA Change
Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
GLENMARK PHARMA 
Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More
Current Valuations
| CIPLA | GLENMARK PHARMA | CIPLA/ GLENMARK PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 23.7 | 12.1 | 195.1% | View Chart |
| P/BV | x | 2.4 | 1.7 | 139.4% | View Chart |
| Dividend Yield | % | 0.7 | 0.6 | 119.1% |
Financials
 CIPLA  GLENMARK PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| CIPLA Mar-19 |
GLENMARK PHARMA Mar-19 |
CIPLA/ GLENMARK PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 678 | 712 | 95.3% | |
| Low | Rs | 484 | 484 | 100.0% | |
| Sales per share (Unadj.) | Rs | 198.2 | 349.6 | 56.7% | |
| Earnings per share (Unadj.) | Rs | 18.5 | 32.8 | 56.5% | |
| Cash flow per share (Unadj.) | Rs | 35.0 | 44.3 | 78.9% | |
| Dividends per share (Unadj.) | Rs | 3.00 | 2.00 | 150.0% | |
| Dividend yield (eoy) | % | 0.5 | 0.3 | 154.3% | |
| Book value per share (Unadj.) | Rs | 186.3 | 198.6 | 93.8% | |
| Shares outstanding (eoy) | m | 805.70 | 282.17 | 285.5% | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 2.9 | 1.7 | 171.5% | |
| Avg P/E ratio | x | 31.4 | 18.2 | 172.0% | |
| P/CF ratio (eoy) | x | 16.6 | 13.5 | 123.2% | |
| Price / Book Value ratio | x | 3.1 | 3.0 | 103.6% | |
| Dividend payout | % | 16.2 | 6.1 | 265.5% | |
| Avg Mkt Cap | Rs m | 468,031 | 168,625 | 277.6% | |
| No. of employees | `000 | 22.6 | 12.0 | 188.1% | |
| Total wages/salary | Rs m | 28,565 | 20,561 | 138.9% | |
| Avg. sales/employee | Rs Th | 7,053.1 | 8,196.0 | 86.1% | |
| Avg. wages/employee | Rs Th | 1,261.5 | 1,708.1 | 73.9% | |
| Avg. net profit/employee | Rs Th | 659.1 | 768.5 | 85.8% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 159,710 | 98,655 | 161.9% | |
| Other income | Rs m | 4,766 | 2,081 | 229.0% | |
| Total revenues | Rs m | 164,475 | 100,736 | 163.3% | |
| Gross profit | Rs m | 30,973 | 15,858 | 195.3% | |
| Depreciation | Rs m | 13,263 | 3,259 | 407.0% | |
| Interest | Rs m | 1,684 | 3,346 | 50.3% | |
| Profit before tax | Rs m | 20,791 | 11,335 | 183.4% | |
| Minority Interest | Rs m | -172 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 1,672 | 0.0% | |
| Tax | Rs m | 5,695 | 3,756 | 151.6% | |
| Profit after tax | Rs m | 14,924 | 9,250 | 161.3% | |
| Gross profit margin | % | 19.4 | 16.1 | 120.6% | |
| Effective tax rate | % | 27.4 | 33.1 | 82.7% | |
| Net profit margin | % | 9.3 | 9.4 | 99.7% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 124,266 | 66,968 | 185.6% | |
| Current liabilities | Rs m | 37,715 | 40,211 | 93.8% | |
| Net working cap to sales | % | 54.2 | 27.1 | 199.8% | |
| Current ratio | x | 3.3 | 1.7 | 197.8% | |
| Inventory Days | Days | 91 | 83 | 108.7% | |
| Debtors Days | Days | 95 | 81 | 116.8% | |
| Net fixed assets | Rs m | 105,190 | 33,322 | 315.7% | |
| Share capital | Rs m | 1,611 | 282 | 571.0% | |
| "Free" reserves | Rs m | 148,511 | 55,770 | 266.3% | |
| Net worth | Rs m | 150,123 | 56,052 | 267.8% | |
| Long term debt | Rs m | 38,301 | 35,738 | 107.2% | |
| Total assets | Rs m | 239,633 | 132,888 | 180.3% | |
| Interest coverage | x | 13.3 | 4.4 | 304.1% | |
| Debt to equity ratio | x | 0.3 | 0.6 | 40.0% | |
| Sales to assets ratio | x | 0.7 | 0.7 | 89.8% | |
| Return on assets | % | 6.9 | 9.5 | 73.1% | |
| Return on equity | % | 9.9 | 16.5 | 60.2% | |
| Return on capital | % | 11.8 | 17.8 | 66.4% | |
| Exports to sales | % | 34.7 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | 55,419 | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 57,410 | 62,998 | 91.1% | |
| Fx outflow | Rs m | 19,041 | 22,859 | 83.3% | |
| Net fx | Rs m | 38,368 | 40,140 | 95.6% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 16,911 | 13,242 | 127.7% | |
| From Investments | Rs m | -16,687 | -6,990 | 238.7% | |
| From Financial Activity | Rs m | -3,487 | -7,387 | 47.2% | |
| Net Cashflow | Rs m | -3,451 | -2,971 | 116.2% | |
Share Holding
| Indian Promoters | % | 16.0 | 48.3 | 33.1% | |
| Foreign collaborators | % | 20.8 | 0.0 | - | |
| Indian inst/Mut Fund | % | 12.2 | 6.9 | 176.8% | |
| FIIs | % | 23.7 | 34.4 | 68.9% | |
| ADR/GDR | % | 1.1 | 0.0 | - | |
| Free float | % | 26.2 | 10.5 | 249.5% | |
| Shareholders | 161,166 | 56,727 | 284.1% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CIPLA With: PFIZER GSK PHARMA PANACEA BIOTECH DR. REDDYS LAB ABBOTT INDIA
Compare CIPLA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)
Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.
Related Views on News
CIPLA 2018-19 Annual Report Analysis (Annual Result Update)
Sep 9, 2019 | Updated on Sep 9, 2019Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Sep 5, 2019 | Updated on Sep 5, 2019Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.
GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)
Aug 28, 2019 | Updated on Aug 28, 2019For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.
GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)
Jun 3, 2019 | Updated on Jun 3, 2019For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
More Views on NewsMost Popular
Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)
Sep 12, 2019News headlines predict gloom and doom for India these days. You should ignore them.
A Recession Proof Stock You Can Bet On(Profit Hunter)
Sep 10, 2019Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.
A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)
Sep 16, 2019The stock market today is throwing up a great opportunity to pile on quality stocks.
This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)
Sep 11, 2019How financial inclusion provides a big runway for this stock recommendation.
The 5 Best Trading Opportunities I've Spotted(Profit Hunter)
Sep 13, 2019These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.
MoreCIPLA SHARE PRICE
Sep 19, 2019 (Close)
TRACK CIPLA
- Track your investment in CIPLA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CIPLA
CIPLA - LUPIN COMPARISON
COMPARE CIPLA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.